Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions

Dermatol Online J. 2023 Feb 15;29(1). doi: 10.5070/D329160209.


Nirmatrelvir-ritonivir (Paxlovid) recently received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19). Literature has linked numerous cutaneous adverse effects to nirmatrelvir and ritonavir, the copackaged tablets within Paxlovid. A review and comparison of these adverse effects to the common cutaneous manifestations of COVID-19 is provided. Numerous drug-to-drug interactions exist between nirmatrelvir-ritonivir and commonly-used medications within dermatology.

MeSH terms

  • COVID-19*
  • Drug-Related Side Effects and Adverse Reactions*
  • Humans
  • Lactams
  • Ritonavir


  • nirmatrelvir and ritonavir drug combination
  • Ritonavir
  • Lactams